Endologix (ELGX) Reports Q4 Loss Per Share of 30c

Endologix (NASDAQ: ELGX) reported Q4 EPS of ($0.30), may not compare to the analyst estimate of ($0.19). Revenue for the quarter came in at $47.5 million versus the consensus estimate of $48.69 million.

GUIDANCE:

Endologix sees FY2017 revenue of $193-200 million, versus the consensus of $199.5 million.

For earnings history and earnings-related data on Endologix (ELGX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c